Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPEL: osimertinib plus platinum-pemetrexed chemotherapy versus placebo plus chemotherapy after progression on first-line osimertinib in EGFR-mutated NSCLC
MOH_2021-05-02_009936Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Osimertinib + platinum-pemetrexed chemotherapy with Placebo + platinum-pemetrexed chemotherapy (2 arms). Primary endpoint: Progression-free survival. Planned start Apr 2021; status: not yet recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2021-05-02_009936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-05-02_009936.